AbbVie CFO discusses strategies; Biz started by former Pfizer folks expanding; Bayer gets Teva animal biz;

@FiercePharma: Here's evidence of Vivus growth expectations: New HQ space almost 3X the size of current offices. More | Follow @FiercePharma

 @EricPFierce: The FDA approved nearly a dozen new cancer drugs in 2012, but also drugs for erectile dysfunction weight-loss. Special Report | Follow @EricPFierce

 @AlisonBFierce: Eli Lilly will step up to the plate to defend against DES litigation. News | Follow @AlisonBFierce

> AbbVie ($ABBV) CFO William Chase says Big Pharma's newest company intends to provide investors with a dividend in the short term while it works on a pipeline of novel drugs for the longer term. Story

> Bayer HealthCare is now the proud owner of the animal health business that it bought from Teva Pharmaceutical Industries ($TEVA) for $60 million up front and up to $85 million in additional payments. Story

> The FDA has turned back another attempt by K-V Pharmaceuticals ($KV.A) to keep competition to its Makena drug for premature births off the market. Story

> Ameridose, which has common ownership with the compounding pharmacy at the heart of the meningitis outbreak that has killed 39, will remain closed another 6 weeks while regulators continue their investigation into "unsanitary conditions." Story

> Watson Pharmaceuticals ($WPI) says the FDA has approved its generic version of Ferring Pharmaceuticals' Lysteda, used for treating heavy menstrual bleeding. Item

> LGC, a company set up by two former Pfizer ($PFE) employees at the former Pfizer site in Kent England, expects to expand this year. Item

Medical Device News

 @FierceMedDev: Halt Medical snags $15M to launch uterine fibroid device. Story | Follow @FierceMedDev

@MarkHFierce: We at Fierce are gearing up for some major coverage of JPM13. The fun starts Monday in San Francisco. Editor's Corner | Follow @MarkHFierce

 @DamianFierce: Hologic is selling off one of the business units it acquired in last year's $3.8B Gen-Probe buy. News | Follow @DamianFierce

> GI Dynamics teams up with Medtronic, GSK for EndoBarrier research. News

> The U.K.'s Wellcome Trust unveils VC fund for devices, Dx and others. Article

> Atossa revs up national sales rollout for handheld breast cancer Dx. Story

Biotech News

 @FierceBiotech: Slideshow: FDA Approvals of 2012. More | Follow @FierceBiotech

@RyanMFierce: $BIIB has filed for FDA approval of long-lasting clotting factor in hemophilia B, a new area for the biotech giant. More | Follow @RyanMFierce

> UCSD biotech spinoff snags $18M A round to advance RNAi drugs. Article

> Amicus jumps on upbeat data for Pompe drug. News

And Finally... A study finds that patients are less likely to take their meds when they are changed to generics whose color or shape is different than the branded products they replaced. Story

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.